Rhythm Pharmaceuticals (RYTM) FCF Margin (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of FCF Margin data on file, last reported at 73.5% in Q1 2026.

• FCF Margin for Q1 2026 came in at 73.5%, up 4988.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 55.03% (up 2789.0% YoY), and the FY2025 annual result was 61.46%, up 2605.0% from the prior year.
• FCF Margin declined to 73.5% in Q1 2026 per RYTM's latest filing, from 44.35% in the prior quarter.
• Over five years, FCF Margin peaked at 422.45% in Q4 2022 and troughed at 3588.72% in Q1 2022.
• A 5-year average of 364.47% and a median of 121.24% in 2023 frame the typical range for FCF Margin.
• The sharpest annual moves came in 2022 and 2023: FCF Margin jumped 9224842 bps in 2022, then slumped 54370 bps in 2023.
• A 5-year view of FCF Margin shows it stood at 422.45% in 2022, then tumbled by 129 bps to 121.24% in 2023, then jumped by 63 bps to 45.05% in 2024, then increased by 2 bps to 44.35% in 2025, then tumbled by 66 bps to 73.5% in 2026.
• Business Quant data shows RYTM's FCF Margin at 73.5% in Q1 2026, 44.35% in Q4 2025, and 51.9% in Q3 2025.